ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK

被引:30
作者
Gao, Danmei [2 ]
Bambang, I. Fon [2 ]
Putti, Thomas C. [2 ]
Lee, Yuan Kun [3 ]
Richardson, Des R. [1 ,4 ]
Zhang, Daohai [1 ,2 ,4 ]
机构
[1] Univ Sydney, Iron Metab & Chelat Program, Dept Pathol, Sydney, NSW 2006, Australia
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore, Singapore
[4] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
drug resistance; ERp29; ER stress; growth arrest; p38; alpha; p58(IPK); DORMANT TUMOR-CELLS; ENDOPLASMIC-RETICULUM; UROKINASE RECEPTOR; CARCINOMA-CELLS; DOWN-REGULATION; IN-VIVO; TRANSCRIPTION FACTOR; GENE-EXPRESSION; KINASE; RNA;
D O I
10.1038/labinvest.2011.163
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Endoplasmic reticulum protein 29 (ERp29) is an ER luminal protein that has a role in protein unfolding and secretion, but its role in cancer is unclear. Recently, we reported that overexpression of ERp29 significantly inhibited cell proliferation and prevented tumorigenesis in highly proliferative MDA-MB-231 breast cancer cells. Here, we show that ERp29-induced cancer cell growth arrest is modulated by the interplay between the concomitant phosphorylation of p38 and upregulation of the inhibitor of the interferon-induced, double-stranded RNA-activated protein kinase, p58(IPK). In this cell model, ERp29 overexpression significantly downregulates modulators of cell proliferation, namely urokinase plasminogen activator receptor, beta(1)-integrin and epidermal growth factor receptor. Furthermore, ERp29 significantly (P<0.001) increases phosphorylation of p38 (p-p38) and reduces matrix metalloproteinase-9 secretion. The role of ERp29 in upregulating cyclin-dependent kinase inhibitors (p15 and p21) and in downregulating cyclin D-2 is demonstrated in slowly proliferating ERp29-overexpressing MDA-MB-231 cells, whereas the opposite response was observed in ERp29-knockdown MCF-7 cells. Pharmacological inhibition of p-p38 downregulates p15 and p21 and inhibits elF2 alpha phosphorylation, indicating a role for p-p38 in this process. Furthermore, p58(IPK) expression was increased in ERp29-overexpressing MDA-MB-231 cells and highly decreased in ERp29-knockdown MCF-7 cells. This upregulation of p58(IPK) by ERp29 suppresses the activation of p-p38/p-PERK/p-elF2 alpha by repressing elF2 alpha phosphorylation. In fact, reduction of p58(IPK) expression by RNA interference stimulated elF2 alpha phosphorylation. The repression of elF2 alpha phosphorylation by p58(IPK) prevents ERp29-transfected cells from undergoing ER-dependent apoptosis driven by the activation of ATF4/CHOP/caspase-3. Hence, the interplay between p38 phosphorylation and p58(IPK) upregulation has key roles in modulating ERp29-induced cell-growth arrest and survival. Laboratory Investigation (2012) 92, 200-213; doi:10.1038/labinvest.2011.163; published online 7 November 2011
引用
收藏
页码:200 / 213
页数:14
相关论文
共 50 条
  • [1] Computational Identification of a p38SAPK-Regulated Transcription Factor Network Required for Tumor Cell Quiescence
    Adam, Alejandro P.
    George, Ajish
    Schewe, Denis
    Bragado, Paloma
    Iglesias, Bibiana V.
    Ranganathan, Aparna C.
    Kourtidis, Antonis
    Conklin, Douglas S.
    Aguirre-Ghiso, Julio A.
    [J]. CANCER RESEARCH, 2009, 69 (14) : 5664 - 5672
  • [2] Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo
    Aguirre-Ghiso, JA
    Liu, D
    Mignatti, A
    Kovalski, K
    Ossowski, L
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) : 863 - 879
  • [3] Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
  • [4] Models, mechanisms and clinical evidence for cancer dormancy
    Aguirre-Ghiso, Julio A.
    [J]. NATURE REVIEWS CANCER, 2007, 7 (11) : 834 - 846
  • [5] RETRACTED: Down-Regulation of uPA and uPAR by 3,3′-Diindolylmethane Contributes to the Inhibition of Cell Growth and Migration of Breast Cancer Cells (Retracted article. See vol. 117, pg. 1959, 2016)
    Ahmad, Aamir
    Kong, Dejuan
    Wang, Zhiwei
    Sarkar, Sanila. H.
    Banerjee, Sanjeev
    Sarkar, Fazlul H.
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 108 (04) : 916 - 925
  • [6] Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-β1 integrin complex in colon cancer cells
    Ahmed, N
    Oliva, K
    Wang, Y
    Quinn, M
    Rice, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 374 - 384
  • [7] The urokinase receptor (u-PAR) - a link between tumor cell dormancy and minimal residual disease in bone marrow?
    Allgayer, Heike
    Aguirre-Ghiso, Julio A.
    [J]. APMIS, 2008, 116 (7-8) : 602 - 614
  • [8] [Anonymous], INT J CELL BIOL
  • [9] Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells
    Bambang, I. Fon
    Xu, Songci
    Zhou, Jianbiao
    Salto-Tellez, Manuel
    Sethi, Sunil K.
    Zhang, Daohai
    [J]. LABORATORY INVESTIGATION, 2009, 89 (11) : 1229 - 1242
  • [10] Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
    Barkan, Dalit
    Kleinman, Hynda
    Simmons, Justin L.
    Asmussen, Holly
    Kamaraju, Anil K.
    Hoenorhoff, Mark J.
    Liu, Zi-yao
    Costes, Sylvain V.
    Cho, Edward H.
    Lockett, Stephen
    Khanna, Chand
    Chambers, Ann F.
    Green, Jeffrey E.
    [J]. CANCER RESEARCH, 2008, 68 (15) : 6241 - 6250